CGRP Receptor Antagonism in COVID-19: Potential Cardiopulmonary Adverse Effects

Recently, the US FDA has authorized a drug repurposing trial with calcitonin gene-related peptide (CGRP) receptor antagonists to reduce lung inflammation in coronavirus 2019 (COVID-19). However, the well-established cardiopulmonary protective effects of CGRP raise concerns about the safety of antago...

Descripción completa

Detalles Bibliográficos
Autores principales: Skaria, Tom, Wälchli, Thomas, Vogel, Johannes
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2021
Materias:
Forum
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7580524/
https://www.ncbi.nlm.nih.gov/pubmed/33129692
http://dx.doi.org/10.1016/j.molmed.2020.10.005
_version_ 1783598809832488960
author Skaria, Tom
Wälchli, Thomas
Vogel, Johannes
author_facet Skaria, Tom
Wälchli, Thomas
Vogel, Johannes
author_sort Skaria, Tom
collection PubMed
description Recently, the US FDA has authorized a drug repurposing trial with calcitonin gene-related peptide (CGRP) receptor antagonists to reduce lung inflammation in coronavirus 2019 (COVID-19). However, the well-established cardiopulmonary protective effects of CGRP raise concerns about the safety of antagonizing CGRP in COVID-19. Awareness regarding potential cardiopulmonary adverse effects may enable their early detection and prevent illness from worsening.
format Online
Article
Text
id pubmed-7580524
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier Ltd.
record_format MEDLINE/PubMed
spelling pubmed-75805242020-10-23 CGRP Receptor Antagonism in COVID-19: Potential Cardiopulmonary Adverse Effects Skaria, Tom Wälchli, Thomas Vogel, Johannes Trends Mol Med Forum Recently, the US FDA has authorized a drug repurposing trial with calcitonin gene-related peptide (CGRP) receptor antagonists to reduce lung inflammation in coronavirus 2019 (COVID-19). However, the well-established cardiopulmonary protective effects of CGRP raise concerns about the safety of antagonizing CGRP in COVID-19. Awareness regarding potential cardiopulmonary adverse effects may enable their early detection and prevent illness from worsening. Elsevier Ltd. 2021-01 2020-10-22 /pmc/articles/PMC7580524/ /pubmed/33129692 http://dx.doi.org/10.1016/j.molmed.2020.10.005 Text en © 2020 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Forum
Skaria, Tom
Wälchli, Thomas
Vogel, Johannes
CGRP Receptor Antagonism in COVID-19: Potential Cardiopulmonary Adverse Effects
title CGRP Receptor Antagonism in COVID-19: Potential Cardiopulmonary Adverse Effects
title_full CGRP Receptor Antagonism in COVID-19: Potential Cardiopulmonary Adverse Effects
title_fullStr CGRP Receptor Antagonism in COVID-19: Potential Cardiopulmonary Adverse Effects
title_full_unstemmed CGRP Receptor Antagonism in COVID-19: Potential Cardiopulmonary Adverse Effects
title_short CGRP Receptor Antagonism in COVID-19: Potential Cardiopulmonary Adverse Effects
title_sort cgrp receptor antagonism in covid-19: potential cardiopulmonary adverse effects
topic Forum
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7580524/
https://www.ncbi.nlm.nih.gov/pubmed/33129692
http://dx.doi.org/10.1016/j.molmed.2020.10.005
work_keys_str_mv AT skariatom cgrpreceptorantagonismincovid19potentialcardiopulmonaryadverseeffects
AT walchlithomas cgrpreceptorantagonismincovid19potentialcardiopulmonaryadverseeffects
AT vogeljohannes cgrpreceptorantagonismincovid19potentialcardiopulmonaryadverseeffects

Ejemplares similares